Learn More
Patients with HTLV-Associated-Myelopathy (pwHAM) predominantly have proximal leg weakness, and reduced activities of daily living (ADLs). 92% of pwHAM attending NCHR use a walking aid and experience difficulty with walking long distances, thus many are housebound, or community ambulators. The 6 minute walk test (6MWT) measures walking endurance and was(More)
INTRODUCTION Patients with HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) become progressively impaired, with chronic pain, immobility and bladder, bowel and sexual dysfunction. Tested antiretroviral therapies have not been effective and most patients are offered a short course of corticosteroids or interferon-α, physiotherapy and(More)
HTLV-1-associated myelopathy (HAM; HTLV-1 is human T-lymphotropic virus type 1) is a chronic debilitating neuroinflammatory disease with a predilection for the thoracic cord. Tissue damage is attributed to the cellular immune response to HTLV-1-infected lymphocytes. The brains of HTLV-1-infected patients, with and without HAM but no clinical evidence of(More)
BACKGROUND Five to ten million persons, are infected by HTLV-1 of which 3% will develop HTLV-1-associated myelopathy (HAM) a chronic, disabling inflammation of the spinal cord. Walking, a fundamental, complex, multi-functional task is demanding of multiple body systems. Restricted walking ability compromises activity and participation levels in people with(More)
Walking, a fundamental, complex, multifunctional task, is demanding of multiple body systems, interactively affecting walking capacity. Due to their restricted walking ability, activity and participation levels in patients with HTLV-1-Associated Myelopathy (pwHAM) are compromised. Primarily, the applicability of walking endurance using the 6 minute walk(More)
Effect of pulsed methylprednisolone on disease severity, viral load and inflammation in patients with human T-lymphotropic virus type 1 associated myelopathy The efficacy of treatments used for patients with HTLV-1 associated myelopathy/tropical spastic paraperesis (HAM/TSP) is uncertain although corticosteroids are widely prescribed. The effect of pulsed(More)
BACKGROUND To advance the treatment of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), randomised controlled therapeutic studies with appropriate and sensitive outcomes are reuired. One candidate outcome is the 10-metre walk test (10MWT), a patient-centred, simple and functional measure. To calculate sample size based on 10MWT as the(More)
HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is an immune mediated myelopathy caused by the human T-lymphotropic virus type 1 (HTLV-1). The efficacy of treatments used for patients with HAM/TSP is uncertain. The aim of this study is to document the efficacy of pulsed methylprednisolone in patients with HAM/TSP. Data from an open(More)
  • 1